SCHEMBL13614222

SCHEMBL13614222

CC(C)(C)OC(=O)N[C@](C)(CCc1ccccc1)COP(=O)(OC(C)(C)C)OC(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA7 P43166 1/20 0.43
CA14 Q9ULX7 1/20 0.43
AKT1 P31749 2/20 0.41
CTSK P43235 3/20 0.39
CTSS P25774 3/20 0.39
SIGMAR1 Q99720 3/20 0.38
AAK1 Q2M2I8 1/20 0.38
ATM Q13315 1/20 0.37
IDO1 P14902 1/20 0.37
CTSL P07711 1/20 0.36
CTSB P07858 1/20 0.36
NPC1 O15118 1/20 0.36
MAPT P10636 1/20 0.36
RAB9A P51151 1/20 0.36
TAAR1 Q96RJ0 1/20 0.36
SSTR4 P31391 1/20 0.36
PPARG P37231 1/20 0.35
PPARA Q07869 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13614220 0.88 CA12 (0.44) CA12CA1CA7CA14AKT1
SCHEMBL3739193 0.83 CTSV (0.42) CTSLNPC1MAPTRAB9A
SCHEMBL3738559 0.82 ALDH1A1 (0.39) CA1AAK1
SCHEMBL13614219 0.81 CA12 (0.51) CA12CA1CA7CA14AKT1
SCHEMBL4818486 0.79 S1PR1 (0.54) PPARG
SCHEMBL86584 0.76 AAK1 (0.40) AAK1PPARGPPARA
SCHEMBL86443 0.76 AAK1 (0.39) AAK1PPARGPPARA
SCHEMBL86253 0.76 AAK1 (0.39) AAK1PPARGPPARA
SCHEMBL295919 0.76 S1PR1 (0.41) AAK1
SCHEMBL13851949 0.75 S1PR1 (0.52) AAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612238-B2 Such as (R)-2-amino-2-methyl-4-[4-(4,4,5,5,5-pentafluoro-pentyloxy)-phenyl]-butan-1-ol hydrochloride for treatment of disorders or diseases mediated by lymphocytes, and for treating acute or chronic transplant rejection or T-cell-mediated inflammatory or autoimmune diseases NOVARTIS AG (CH) 2009-11-03 US disclosed